Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Benzodiazepines
11 evidence topics · 9 sources
FDA-approved indication: alprazolam
Approval status and off-label use of individual benzodiazepines
“As such, alprazolam is the only benzodiazepine to be formally approved by the FDA for the treatment of GAD. However, clonazepam, lorazepam, and diazepam are often used to treat GAD in adults” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Benzodiazepines such as diazepam and clonazepam (both of which are long-acting agents) may be efficacious in treating GAD, although many clinicians choose to limit their use due to concerns about the risks regarding possible misuse and dependence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
FDA boxed warning for the benzodiazepine class, September 2020
Benzodiazepine prescribing, misuse, and overdose data
Boxed warning in the alprazolam prescribing information
NICE guideline: short-term use during crises only
CANMAT guideline: second-line agents for short-term use
“While these agents have level 1 evidence for efficacy, they are recommended as second-line therapy, and usually only for short-term use, because of side effects, dependence, and withdrawal issues.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within these second-line agents, benzodiazepines would be considered first in most cases, except where there is a risk of substance abuse, while bupropion XL would likely be reserved for later.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second-line choices include bupropion XL, buspirone, hydroxyzine, imipramine, quetiapine XR, vortioxetine, as well as the benzodiazepines, alprazolam, bromazepam, diazepam, and lorazepam.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BAP guideline: use after nonresponse to other treatments
AAFP review: onset, dependence, and position in therapy
Meta-analysis: benzodiazepines compared with SSRIs and SNRIs
“A comprehensive literature search yielded 54 articles reporting 56 unique studies with 12,655 participants treated with either pill placebo (6,191 participants), SSRIs (16 trials, 2,712 participants), SNRIs (17 trials, 2,603 participants), or BZs (23 trials, 1,149 participants).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SSRIs (Hedges’ g = 0.33) and SNRIs (Hedges’ g = 0.36) demonstrated significantly lower effect sizes than BZs (Hedges’ g = 0.50).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote